Regression of Liver Steatosis Following Phosphatidylcholine Administration: A Review of Molecular and Metabolic Pathways Involved.

Autor:	Osipova D; Research Centre for Medical Genetics, Moscow, Russia., Kokoreva K; Institute of Pediatric Endocrinology, Endocrinology Research Centre, Moscow, Russia., Lazebnik L; A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia., Golovanova E; A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia., Pavlov C; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia., Dukhanin A; Molecular Pharmacology and Radiology Department, Russian National Research Medical University, Moscow, Russia., Orlova S; Department of Dietetics and Clinical Nutrition of Continuing Medical Education, Medical Institute, RUDN University, Moscow, Russia., Starostin K; Science Hub, Sanofi, Moscow, Russia.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2022 Mar 10; Vol. 13, pp. 797923. Date of Electronic Publication: 2022 Mar 10 (Print Publication: 2022).
DOI:	10.3389/fphar.2022.797923
Abstrakt:	Liver steatosis is a key pathology in non-alcoholic or metabolic associated fatty liver disease. Though largely ignored for decades it is currently becoming the focus of research in hepatology. It is important to consider its origin and current opportunities in terms of pharmacotherapy. Essential phospholipids (EPLs) rich in phosphatidylcholine (PCH) is a widely used treatment option for fatty liver disease, and there is a solid amount of consistent clinical evidence for the regression of steatosis after treatment with EPLs. As knowledge of PCH (a key component of EPLs) pharmacodynamics and mode of action driving this widely observed clinical effect is currently insufficient, we aimed to explore the potential molecular and metabolic pathways involved in the positive effects of PCH on steatosis regression. Competing Interests: KS is a Sanofi employee. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Osipova, Kokoreva, Lazebnik, Golovanova, Pavlov, Dukhanin, Orlova and Starostin.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu